v3.26.1
Condensed Statements of Stockholders' Equity (Deficit) - USD ($)
Total
Elevai Acquisition
Preferred Stock [Member]
Series A Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Elevai Acquisition
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Elevai Acquisition
Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2023 $ 24,749,010   $ 1 $ 77   $ 83,252,333   $ (58,503,401)
Beginning Balance (in Shares) at Dec. 31, 2023     4,243 769,808        
Stock received from AxoBio Disposition (23,456,179)   $ (1) $ (12)   (23,456,166)    
Stock received from AxoBio Disposition (in Shares)     (4,243) (128,178)        
Common Stock issued 2,687,225     $ 4   2,687,221    
Stock shares issued during the period shares       44,382        
Common Stock issued in connection with Notes 848,500     $ 1   848,499    
Common Stock issued in connection with Notes (in Shares)       10,957        
Stock-based compensation expense 827,043         827,043    
Net Income (Loss) (10,368,261) $ (10,368,261)           (10,368,261)
Ending Balance at Dec. 31, 2024 (4,712,662)     $ 70   64,158,930   (68,871,662)
Ending Balance (in Shares) at Dec. 31, 2024       696,969        
Common Stock issued 3,397,476 660,805   $ 74 $ 4 3,397,402 $ 660,801  
Stock shares issued during the period shares       748,461 38,308      
Exercise of Common Stock warrants, (in shares)       298,000        
Exercise of common stock warrants 1,000,000     $ 30   999,970    
Stock-based compensation expense 692,790         692,790    
Net Income (Loss) (6,905,282) $ (6,905,282)           (6,905,282)
Ending Balance at Dec. 31, 2025 $ (5,866,873)     $ 178   $ 69,909,893   $ (75,776,944)
Ending Balance (in Shares) at Dec. 31, 2025       1,781,738